image: The peptide Pal-DMPOP consists a peptide inhibitor of CD47/SIRPα, a D-peptide inhibitor of PD-1/PD-L1, and a palmitic acid tail conjugated at its N-terminal through a PEG4 linker. This design made this peptide resistant to serum proteolysis and accumulated in the tumor tissues. It can block CD47/SIRPα and PD-1/PD-L1 to enhance the phagocytosis of macrophage, and block PD-1/PD-L1 to restore the function of T cell. view more
Credit: ©Science China Press
SCIENCE CHINA Life Sciences published a research article online by Professor Yanfeng Gao’s team from the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University. They designed and synthesized Pal-DMPOP, a chimeric peptide that can simultaneously block CD47/SIRPα and PD-1/PD-L1. This bispecific peptide elicits synergistic antitumor activity by enhancing macrophages phagocytosis and activating CD8+ T cells.
Although immune checkpoint inhibition has been shown to effectively activate antitumor immunity in various tumor types, only a small subset of patients can benefit from PD-1/PD-L1 blockade. CD47 expressed on tumor cells protects them from phagocytosis through interaction with SIRPα on macrophages, while PD-L1 dampens T cell-mediated tumor killing. Also, it was reported that macrophages can also express PD-1 to mediate “don’t eat me” signal through interaction with PD-L1 on tumor cells. Compared with antibodies, peptides have better tumor penetration ability and easy to be synthesized. Therefore, design of peptides dual-targeting blockade of both PD-1/PD-L1 and CD47/SIRPα may improve the efficacy of cancer immunotherapy.
In this article, the authors designed a chimeric peptide Pal-DMPOP. It consists of the smallest fragment of the D-peptide inhibitor of PD-1/PD-L1 (OPBP-1) and the optimized peptide inhibitor of CD47/SIRPα (Pep-20). Also, the palmitic acid tail was modified at its N-terminal to improve its anti-enzymatic ability and in vivo half-life. The research team verified that Pal-DMPOP can improve the phagocytosis of macrophages on tumor cells, and can also restore the killing effect of CD8+T cells on tumor cells in vitro. The effect of tumor immunotherapy in vivo has been determined in MC38 and CT26 mouse models. The tumor volume in Pal-DMPOP administration group is significantly reduced compared with the control group, and Pal-DMPOP has no obvious toxic effect in the tumor-bearing mice.
See the article:
Journal
Science China Life Sciences